Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia
- PMID: 25645393
- DOI: 10.1016/j.neuropharm.2015.01.012
Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia
Abstract
Serotonin 5-HT1A receptor agonists reduce L-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease (PD). Here, we compared the effects of novel 5-HT1A receptor 'biased agonists' on LID in hemiparkinsonian rats. F13714 preferentially activates pre-synaptic 5-HT1A autoreceptors. F15599 preferentially activates cortical postsynaptic 5-HT1A heteroreceptors. The partial agonist, tandospirone, does not differentiate these receptor subpopulations. The drugs were also tested on rotational behavior, rotarod and cylinder test for evaluation of locomotor activity, motor coordination and forelimb akinesia. Finally, the effects of F13714 and F15599 on 5-HT, DA, glutamate, and GABA release were investigated by microdialysis. F13714 abolished L-DOPA-induced AIMs even at very low doses (0.02-0.04 mg/kg). This effect was reversed by the selective 5-HT1A receptor antagonist, WAY100635. F13714 also elicited ipsilateral rotations (which were blocked by WAY100635) and potentiated the rotational activity of a sub-threshold dose of L-DOPA (2 mg/kg). F13714 profoundly inhibited striatal 5-HT release on both sides of the brain, and slightly increased DA release on the intact side. F15599 inhibited the L-DOPA-induced AIMs only at a dose (0.16 mg/kg) that reduced 5-HT release. Tandospirone produced a modest attenuation of peak AIMs severity and did not elicit rotations. F13714, F15599 and tandospirone did not modify the action of L-DOPA in the cylinder test but impaired rotarod performance at the highest doses tested. Targeting 5-HT1A receptors with selective biased agonists exerts distinct effects in the rat model of PD and LID. Preferential activation of 5-HT1A autoreceptors could potentially translate to superior antidyskinetic and L-DOPA dose-sparing effects in PD patients.
Keywords: 5-HT; 5-HT(1A) receptor; 6-OHDA rat model of PD; Biased agonist; Dopamine, serotonin; Parkinson's disease; l-DOPA; l-DOPA-Induced dyskinesia.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.Exp Neurol. 2015 Sep;271:335-50. doi: 10.1016/j.expneurol.2015.05.021. Epub 2015 May 30. Exp Neurol. 2015. PMID: 26037043
-
Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia.Exp Neurol. 2017 Jun;292:168-178. doi: 10.1016/j.expneurol.2017.03.013. Epub 2017 Mar 23. Exp Neurol. 2017. PMID: 28342749
-
Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following L-DOPA Administration in Hemi-Parkinsonian Rats.Neurochem Res. 2018 May;43(5):1035-1046. doi: 10.1007/s11064-018-2514-y. Epub 2018 Mar 23. Neurochem Res. 2018. PMID: 29572645
-
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.Prog Brain Res. 2008;172:479-94. doi: 10.1016/S0079-6123(08)00923-0. Prog Brain Res. 2008. PMID: 18772047 Review.
-
5-HT1A agonists for levodopa-induced dyskinesia in Parkinson's disease.Neurodegener Dis Manag. 2023 Apr;13(2):101-112. doi: 10.2217/nmt-2022-0039. Epub 2023 May 4. Neurodegener Dis Manag. 2023. PMID: 37140165 Review.
Cited by
-
Serotonin as a biomarker of toxin-induced Parkinsonism.Mol Med. 2024 Mar 1;30(1):33. doi: 10.1186/s10020-023-00773-9. Mol Med. 2024. PMID: 38429661 Free PMC article.
-
Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research.Metab Brain Dis. 2023 Mar;38(3):873-919. doi: 10.1007/s11011-023-01180-z. Epub 2023 Feb 20. Metab Brain Dis. 2023. PMID: 36807081 Review.
-
Histological Correlates of Neuroanatomical Changes in a Rat Model of Levodopa-Induced Dyskinesia Based on Voxel-Based Morphometry.Front Aging Neurosci. 2021 Oct 28;13:759934. doi: 10.3389/fnagi.2021.759934. eCollection 2021. Front Aging Neurosci. 2021. PMID: 34776935 Free PMC article.
-
Glutamic Acid Transporters: Targets for Neuroprotective Therapies in Parkinson's Disease.Front Neurosci. 2021 Jun 16;15:678154. doi: 10.3389/fnins.2021.678154. eCollection 2021. Front Neurosci. 2021. PMID: 34220434 Free PMC article. Review.
-
Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia.J Exp Pharmacol. 2021 Apr 29;13:469-485. doi: 10.2147/JEP.S265282. eCollection 2021. J Exp Pharmacol. 2021. PMID: 33953618 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources